Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Generic Drugs Strategy Pricing Debate

Waverley Weighs Its Options With High Costs, Thin Margins

Small Molecule Oncology Specialist Battered By Competition

  • News

Executive Summary

Waverley is evaluating options for its generics as it looks likely to throw its all at the company’s lead product candidate in the hopes of luring a development partner or buyer.

You may also be interested in...



Alimta ANDA Products Hit Double Digits With Several Launches

Following patent expiry on 24 May, Alimta ANDA products have reached the US market, eating into a product that generated more than $1.2bn in sales last year.

Waverley Lists In Frankfurt

Canadian generic oncology specialist Waverley Pharma has cross-listed on the Frankfurt Stock Exchange.

Hybrid Specialist Azurity Snaps Up Complex Generics Firm Slayback Pharma

In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.

Table

View full table

Topics

Tags:
Generic Drugs Strategy Pricing Debate
Latest Headlines

Hybrid Specialist Azurity Snaps Up Complex Generics Firm Slayback Pharma

Shortlist Revealed Ahead Of October Awards

Teva Looks To Novartis To Replace Departing Dethlefs

US Court Says Yes To Gilead’s Quarter Billion Dollar Settlement On Truvada, Atripla

See All
UsernamePublicRestriction

Register

GB152599

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By